Alessandro Palumbo currently serves as Senior Director at NGM Biopharmaceuticals, where he leverages his extensive expertise in antibody therapeutics to drive innovative research and development initiatives. With a strong foundation in molecular biology and cell culture, Alessandro is at the forefront of advancing biologics, particularly...
Alessandro Palumbo currently serves as Senior Director at NGM Biopharmaceuticals, where he leverages his extensive expertise in antibody therapeutics to drive innovative research and development initiatives. With a strong foundation in molecular biology and cell culture, Alessandro is at the forefront of advancing biologics, particularly in the areas of antibody engineering and discovery. His role encompasses overseeing key projects that focus on the isolation and development of therapeutic antibodies, utilizing cutting-edge in vivo and in vitro technologies to address complex disease areas, including cancer.
At NGM, Alessandro leads a multidisciplinary team dedicated to the optimization of cell line development and expression systems, ensuring that the therapeutic candidates not only meet efficacy benchmarks but also demonstrate safety and manufacturability. His proficiency in techniques such as Western blotting, PCR, and immunohistochemistry enables him to guide his team through the intricacies of biologics development, from initial discovery phases to preclinical evaluation.
In addition to his technical acumen, Alessandro excels in project and people management, fostering a collaborative environment that encourages innovation and scientific rigor. His strategic vision and leadership have been instrumental in advancing NGM's pipeline, positioning the company as a leader in the biopharmaceutical landscape. As he continues to explore new frontiers in antibody therapeutics, Alessandro remains committed to translating scientific discoveries into impactful treatments that can significantly improve patient outcomes.
